The solution to tackle the hemodialysis site blockage
Clinical Problem
Chronic kidney disease is a serious and growing health problem affecting millions of patients worldwide.
Today 4.5M patients worldwide suffering of end-stage kidney disease (ESKD) require hemodialysis to replace their kidney function.
Hemodialysis is a long and very restrictive life-saving procedure performed 3 times a week.
To connect the patient to the machine, the best and safest approach is to create a vascular access
Vascular access is the connection between an artery and a vein realized by a surgeon as a arteriovenous fistula (AVF). This is the patient’s lifeline
In the first 6 months after surgery, more than 50% of these AVFs will suffer failure resulting in the blockage of the AVF.
At ArtemiX Biotech, we address this treatment gap.
Our Solution
ArtemiX provides a new generation, patented, long-acting gel administered directly on the AVF after the surgery, helping the AVF to mature (heal) and preventing the blockage of blood flow through the vein.
- Unique Mode of Action
Once in place, the gel releases on the long term the active drug, inhibiting all stages of disease.
- Compliance with human biology
Biodegradable formulation.
- Very Simple to apply
Right after the arterio-venous surgery, the gel is very easily applied around the vessel by the surgeon without any added surgical procedure.
About Us
Artemix Biotech is an early clinical stage spin-off company of the University Hospital of Lausanne and School of Pharmaceutical Sciences of the University of Geneva.
Our products are still under development and not available on the market.
Laurent Vinet
CEO
Nasreddine Kanfar
Scientific collaborator
Florence Delie
Advisor
Francois Saucy
Advisor
Olivier Jordan
Advisor
News
Our Supporters
